13.45
price up icon0.30%   0.04
after-market Dopo l'orario di chiusura: 13.12 -0.33 -2.45%
loading

Perché le azioni Keros Therapeutics Inc (KROS) sono in ribasso?

Abbiamo notato un calo di 6.32% nelle azioni di Keros Therapeutics Inc (KROS) durante la sessione di negoziazione di 2025-06-09. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-12-11:

Shares of Keros Therapeutics Inc (KROS) dropped by 20.53% from $35.65 to $28.33 in the trading on Monday, December 11, 2023. The reason why KROS down today is due to the company's presentation of additional data from its Phase 2 clinical trials of KER-050. These trials target patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF). The data was shared at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held from December 9 to 12, 2023. Keros Therapeutics presented data from its Phase 2 trials of KER-050, addressing MDS and MF. Additionally, preclinical data showed the potential of KER-050 to promote erythropoiesis in an animal model of MF. The presentation also included preclinical data related to activin receptor-like kinase 2 inhibition in a mouse model of iron-refractory iron deficiency anemia. The market's reaction to these updates led to the significant decline in KROS shares. Investors will continue to watch for developments in KER-050's clinical outcomes and their impact on the company's future prospects.

$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Capitalizzazione:     |  Volume (24 ore):